Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458593 | 0.91 | HTR6 (0.44) | POLBALDH1A1HTTLMNAHTR6 | |
| SCHEMBL17464712 | 0.90 | HTR6 (0.42) | CNR2HTR6 | |
| SCHEMBL17458532 | 0.88 | HTR6 (0.41) | HPGDPOLBSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL17458529 | 0.87 | HTR2A (0.43) | POLBSMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL17458536 | 0.87 | TP53 (0.39) | KDM4EPOLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17464753 | 0.87 | TP53 (0.39) | POLBLMNA | |
| SCHEMBL17464760 | 0.87 | KDM4E (0.42) | KDM4ECNR2HPGDPOLBSMN1; SMN2 | |
| SCHEMBL17456761 | 0.87 | KDM4E (0.42) | KDM4ECNR2HPGDPOLBSMN1; SMN2 | |
| SCHEMBL17464759 | 0.87 | TP53 (0.37) | POLBKMT2AMEN1 | |
| SCHEMBL17453836 | 0.86 | KDM4E (0.43) | KDM4ECNR2HPGDPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | claimed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | claimed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | claimed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | KDM4E 3687/4885CNR2 633/4885HPGD 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.